ANAPTYSBIO, INC

Overview

Compare with Akebia Therapeutics, Inc., Puma Biotechnology or Keros Therapeutics, Inc., or pick any stock.

• TickerANAB on Nasdaq²
• IndustryPharmaceutical Preparations²
• HeadquartersSan Diego, United States²
• Incorporated inDE⁴
• Business address10770 Wateridge Circle, Suite 210, San Diego, Ca 92121⁴
• Filer categoryNon-accelerated filer, Smaller reporting company⁴
• Legal formCorporation²
• LEI529900HH4WQT03IG1A12²
• StatusActive²
• LEI statusLapsed (not renewed)²
• Registered addressc/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States²
• Registered withDivision of Corporations, Department of State, 4062359²

See how the biggest companies compare on our leaderboards

We are a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Our clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which we completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (“RA”), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (“CeD”) and eosinophilic esophagitis (“EoE”), and ANB101, a BDCA2 modulator, in a Phase 1a trial. We also discovered and out-licensed, in financial collaborations, multiple therapeutic antibodies, including a PD-1 antagonist (Jemperli (dostarlimab-gxly) or “Jemperli”) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals Inc. (“Vanda”). We currently recognize revenue from milestones and royalties achieved under our immuno-oncology collaboration with GSK and license and…⁶ From its latest annual report

Corporate structure

ANAPTYSBIO, INC sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What ANAPTYSBIO, INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Properties, in its own words

Our principal executive office is located at 10770 Wateridge Circle in San Diego, California, and consists of approximately 45,000 square feet of leased office and laboratory space under a lease for a term of 124 months, beginning on April 5, 2021. The terms of the Lease Agreement provide us with an option to extend the term of the lease for an additional five years, as well as a one-time option to terminate the lease after seven years with the payment of a termination fee. We subleased all of this facility to First Tracks Biotherapeutics, as of June 15, 2026.

We believe that our facilities are sufficient to meet our current needs and that suitable additional space will be available as and when needed.

Item 2 of the 10-KT filed Sep 21, 2026.¹⁸

Leadership

Who has led ANAPTYSBIO, INC, and when. Pick a name to see everywhere that person has worked.

• Chief executive officerDaniel Faga Mar 23, 2022 to now¹⁹
• Chief executive officerHamza Suria Jan 25, 2017 to Feb 14, 2022²⁰
• PresidentDaniel Faga Jan 7, 2025 to now²¹
• PresidentHamza Suria Jan 25, 2017 to Feb 14, 2022²⁰
• Chief financial officerChristopher M. Murphy May 13, 2026 to now²²
• Chief financial officerDennis Mulroy Jul 15, 2020 to May 13, 2026²³
• Chief financial officerEric J. Loumeau Aug 20, 2019 to Dec 10, 2019²⁴
• Chief financial officerDominic Piscitelli Jan 25, 2017 to Feb 11, 2019²⁵
• Chief operating officerEric J. Loumeau Jul 15, 2020 to Jan 10, 2023²⁶

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

• AnaptysBio Pty Ltd Australia⁵

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

• ANAPTYSBIO INCAug 27, 2008 to Jun 12, 2019⁴
• ANAPTYS BIOSCIENCES INCJul 6, 2006 to Nov 20, 2007⁴

Timeline

1. Sep 21, 20268-K Financial statements and exhibits⁴⁷
2. Aug 11, 20268-K Shareholder vote⁴⁸
3. Jul 30, 20268-K Regulation FD disclosure⁴⁹
4. Jun 22, 20268-K Entered a material agreement⁵⁰
5. May 29, 20268-K Regulation FD disclosure⁵¹
6. May 21, 20268-K Bylaws or fiscal year changed⁵²
7. May 12, 20268-K Results of operations⁵³
8. May 11, 20268-K Executive or director change⁵⁴
9. Apr 24, 20268-K Financial statements and exhibits⁵⁵
10. Apr 20, 20268-K Entered a material agreement; Completed an acquisition or sale; Executive or director change⁵⁶
11. Mar 27, 20268-K Entered a material agreement; Ended a material agreement; Executive or director change⁵⁷
12. Mar 3, 20268-K Results of operations; Regulation FD disclosure⁵⁸
13. Mar 23, 2022New chief executive Daniel Faga becomes CEO¹⁹
14. Jan 25, 2017New chief executive Hamza Suria becomes CEO²⁰

Calendar

Coming up

1. Nov 3, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.52 a share, on Nov 4, 2025.⁵⁹

When it reported results

1. May 12, 2026Reported quarterly or annual results⁵³
2. Mar 3, 2026Reported quarterly or annual results⁵⁸
3. Jan 9, 2026Reported quarterly or annual results⁶⁰
4. Nov 4, 2025Reported quarterly or annual results⁶¹
5. Aug 6, 2025Reported quarterly or annual results⁶²
6. May 5, 2025Reported quarterly or annual results⁶³
7. Feb 27, 2025Reported quarterly or annual results⁶⁴
8. Nov 5, 2024Reported quarterly or annual results⁶⁵

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

406 filings to the SEC since October 2021: 7 annual reports, 14 quarterly reports, 67 major events, 169 insider forms, 50 large holders, 99 other. The latest 20:

1. Oct 2, 20264 EDGAR
2. Oct 1, 2026144 EDGAR
3. Sep 21, 202610-KT EDGAR
4. Sep 21, 20268-K EDGAR
5. Sep 17, 20264 EDGAR
6. Aug 14, 2026SCHEDULE 13G/A EDGAR
7. Aug 11, 20268-K EDGAR
8. Aug 7, 20264 EDGAR
9. Aug 7, 20264 EDGAR
10. Jul 30, 20268-K EDGAR
11. Jul 13, 2026144 EDGAR
12. Jun 30, 2026144 EDGAR
13. Jun 29, 2026144 EDGAR
14. Jun 29, 2026ARS EDGAR
15. Jun 29, 2026DEFA14A EDGAR
16. Jun 29, 2026DEF 14A EDGAR
17. Jun 26, 2026144 EDGAR
18. Jun 22, 20268-K EDGAR
19. Jun 17, 2026144 EDGAR
20. Jun 17, 20264 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

70 open-market trades by officers, directors and large owners since October 2021: 5 buys and 65 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Sirenia Capital Management LPSCHEDULE 13G/A, 2 filings May 15, 2026 to Aug 14, 2026⁶⁶
• Point72 Asset Management, L.P.SCHEDULE 13G/A, 7 filings Feb 14, 2022 to May 15, 2026⁶⁷
• VANGUARD GROUP INCSCHEDULE 13G/A, 6 filings Feb 9, 2022 to Mar 26, 2026⁶⁸
• Morgan StanleySCHEDULE 13G/A, 2 filings Aug 5, 2025 to Feb 11, 2026⁶⁹
• MILLENNIUM MANAGEMENT LLCSCHEDULE 13G/A, 2 filings Sep 23, 2025 to Jan 16, 2026⁷⁰
• First Light Asset Management, LLCSCHEDULE 13G/A, 3 filings Mar 7, 2025 to Nov 14, 2025⁷¹
• Goldman SachsSCHEDULE 13G/A, 2 filings May 12, 2025 to Nov 12, 2025⁷²
• FMR LLCSCHEDULE 13G/A, 3 filings Jul 10, 2024 to Jun 6, 2025⁷³
• BlackRockSCHEDULE 13G/A, 5 filings Feb 3, 2022 to Apr 17, 2025⁷⁴
• Fairmount Funds Management LLCSCHEDULE 13G/A, 2 filings Dec 18, 2024 to Feb 14, 2025⁷⁵
• Frazier Life Sciences Public Fund, L.P.SCHEDULE 13G/A, 3 filings May 6, 2024 to Feb 14, 2025⁷⁶
• Deep Track Capital, LPSC 13G/A, 3 filings Oct 2, 2023 to Nov 14, 2024⁷⁷
• TANG CAPITAL MANAGEMENT LLCSC 13G/A, 1 filing Nov 14, 2024⁷⁸
• EcoR1 Capital, LLCSC 13D/A, 1 filing Aug 16, 2024⁷⁹
• TANG CAPITAL PARTNERS LPSC 13G/A, 1 filing Feb 14, 2024⁸⁰
• James E. FlynnSC 13G/A, 2 filings Aug 15, 2022 to Feb 10, 2023⁸¹
• Federated HermesSC 13G/A, 4 filings Feb 14, 2022 to Feb 9, 2023⁸²
• PERCEPTIVE ADVISORS LLCSC 13G/A, 1 filing Feb 15, 2022⁸³

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How ANAPTYSBIO, INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARANAPTYSBIO, INC¹
• CIK0001370053
• Employer ID (EIN)20-3828755¹⁸
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company¹⁸
• Incorporated inDelaware¹⁸
• Fiscal year endsJune 30¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address10770 Wateridge Circle, Suite 210, San Diego, CA 92121¹
• Phone858-362-6295¹
• Shares outstanding29,895,244 shares as of Sep 16, 2026¹⁸
• Public float$632.7M as of Dec 31, 2025¹⁸
• AuditorKPMG LLP, San Diego, California PCAOB ID 185; no auditor attestation of internal control over financial reporting¹⁸
• On EDGAR sinceJul 6, 2006¹
• Filings725 in all: 4 (266), 8-K (115), 144 (68), SC 13G/A (43), 3 (30), 10-Q (28), SC 13G (23), SCHEDULE 13G/A (17)¹
  All 40 form types

  CORRESP (14), 10-K (10), S-8 (10), DEF 14A (9), DEFA14A (9), UPLOAD (9), S-1/A (8), SCHEDULE 13G (8), REGDEX (7), SC 13D/A (7), 424B5 (5), D (5), ARS (4), EFFECT (4), SC 13D (3), 10-K/A (2), 10-Q/A (2), 424B4 (2), DRS (2), S-1 (2), S-3 (2), 10-KT (1), 4/A (1), 8-A12B (1), 8-K/A (1), CERTNAS (1), CT ORDER (1), DRS/A (1), DRSLTR (1), POS EX (1), PRE 14A (1), S-3ASR (1)

• Latest filingsAnnual report (10-KT) Sep 21, 2026
  Quarterly report (10-Q) May 12, 2026
  Proxy statement (DEF 14A) Jun 29, 2026
  Latest 8-K (8-K) Sep 21, 2026

Securities registered for trading

From the cover page of the 10-KT filed Sep 21, 2026 (Section 12(b) of the Exchange Act).¹⁸

Risk factors and legal proceedings

The risks ANAPTYSBIO, INC names in Item 1A of its 10-KT filed Sep 21, 2026: 43 risks under these headings, as written.¹⁸

• Risks Related to Continued Commercialization Success of Jemperli
• We derive substantially all of our revenues from GSK’s commercialization of Jemperli. As a result, our business and financial results and prospects heavily depend on GSK’s ability to successfully develop and commercialize Jemperli.
• Our existing collaboration with GSK and other collaborations, including with Vanda, are important to our business, and other future collaborations may also be important to our business. If we are unable to maintain the GSK collaboration, or if this collaboration is not successful, our business could be adversely affected and the price of our securities could fall.
• When the FDA or other applicable regulatory authorities approve generic products, including but not limited to generic forms of Keytruda®, which competes with Jemperli, the royalties payable to us pursuant to the GSK Agreement may be less than anticipated, which in turn would harm our business and cause the price of our securities to fall.
• Reduced prices and reimbursement rates due to the actions of governments, payors, or competition or other healthcare cost containment initiatives such as restrictions on use, may negatively impact royalties generated under the GSK Agreement.
• If the commercialization of Jemperli in the countries in which it has received regulatory approval encounters any delays or adverse developments, or perceived delays or adverse developments, or if sales or payor coverage does not meet investors’, analysts’, or our expectations, our business will be harmed and the price of our securities could fall.
• We are heavily dependent on GSK for the successful commercialization and development of Jemperli under the GSK Agreement. If GSK does not devote sufficient resources to the commercialization or development of Jemperli, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed.
• Any adverse developments to the regulatory status of Jemperli in the countries in which it has received regulatory approval, including labeling restrictions, safety findings, or any other limitation to usage, would harm our business and may cause the price of our securities to fall.
• Jemperli faces substantial competition for its intended uses in the targeted markets from products discovered, developed and commercialized both by GSK and by other pharmaceutical companies, which could cause the royalties payable to us pursuant to the GSK Agreement to be less than expected, which in turn would harm our business and cause the price of our securities to fall.
• Risks Related to Intellectual Property
• Our royalty revenues depend on patent rights licensed to third parties, and if we or our licensees or collaborators are unable to obtain, maintain, and protect those patent rights, our royalty revenues and the value of our patent portfolio may be materially adversely affected.
• We may have limited control over patent prosecution, maintenance, enforcement, defense, patent listings, patent term extensions and related intellectual property strategy for licensed products, and our licensees’ or collaborators’ interests may not align with ours.

Legal proceedings

On November 20, 2025, we filed a Verified Complaint in Delaware Chancery Court (the “Court”), requesting a court declaration that TESARO, Inc. (“Tesaro”) has materially breached the parties’ Collaboration and Exclusive License Agreement (“Collaboration Agreement”) and that GSK, Tesaro’s corporate parent, has tortiously interfered with the Collaboration Agreement. We have requested that the court declare that we are entitled to all rights and remedies under the Collaboration Agreement.

While we had approached Tesaro to engage in good faith discussions to potentially resolve these claims, on November 20, 2025, Tesaro, without notice, initiated a lawsuit against us. Tesaro’s complaint includes a request for a declaration that it has not breached the Collaboration Agreement and for an injunction prohibiting AnaptysBio from terminating the Collaboration Agreement.

The opening of Item 3, Legal Proceedings.¹⁸